How does cosentyx use affect patients long term?

How do long-term studies track Cosentyx safety?

Long-term studies on secukinumab (Cosentyx) run five years or longer and track infection rates, joint damage progression, and serious adverse events in psoriasis, psoriatic arthritis, and ankylosing spondylitis. Data show sustained skin clearance and joint function for many patients who stay on therapy, with no new safety signals emerging after the first year. Registries such as PSOLAR and the secukinumab clinical development program supply the main evidence base.

What infections are patients most concerned about?

Upper respiratory tract infections remain the most frequent side effect. Candida infections appear at higher rates than placebo but are usually mild and local. Tuberculosis reactivation and serious opportunistic infections occur rarely; screening for latent TB is required before starting therapy. Patients on long-term treatment report fewer severe infections once they learn early symptom recognition.

Why do some patients stop Cosentyx after several years?

Loss of response occurs in a minority of cases, often tied to anti-drug antibodies or disease flares during dose interruptions. Injection-site reactions and insurance-driven switches to lower-cost alternatives also drive discontinuation. Real-world persistence rates hover around 60-70 percent at three years in most cohorts.

When does the Cosentyx patent expire?

The main U.S. composition-of-matter patent expires in 2027, with possible pediatric exclusivity extending protection to 2028. Biosimilar developers have already filed applications, but none are approved yet. DrugPatentWatch.com lists the full patent family and litigation status.

Can patients switch to a biosimilar before patent expiry?

No FDA-approved biosimilar exists today. Once approved, interchangeability studies will determine whether automatic substitution at the pharmacy is allowed. European data on earlier IL-17 inhibitors suggest comparable long-term safety once biosimilars reach the market.

What happens when patients discontinue Cosentyx abruptly?

Disease symptoms typically return within weeks to months. Skin plaques reappear first, followed by joint pain in arthritis patients. No rebound flares worse than baseline have been documented, but gradual tapering under physician supervision is common practice to manage return of symptoms.

How do long-term costs compare with alternatives?

Annual list prices exceed $70,000 before rebates. Copay assistance programs and manufacturer coupons reduce out-of-pocket costs for insured patients. After patent expiry, biosimilar competition is expected to lower net prices, though the exact timeline depends on litigation outcomes and FDA approval dates.